Lanepitant, an NK-1 antagonist, in migraine prevention

Cephalalgia

Volumn 21, Issue 2, 2001, Pages 102-106

  Goldstein, David J ^a,b,c   Offen, W W ^a   Klein, E G ^a   Phebus, L A ^a   Hipskind, P ^a   Johnson, K W ^a   Ryan Jr , R E ^d  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Ryan Headache Center   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d NONE

Author keywords

Headache; Migraine prophylaxis; Neurokinin 1 antagonist; Substance P antagonist

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE; LANEPITANT; NEUROKININ; NEUROKININ 1 RECEPTOR; PLACEBO; SUBSTANCE P;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEART PALPITATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; NAUSEA; NOCICEPTION; RANDOMIZED CONTROLLED TRIAL; SLEEP DISORDER; STATISTICAL ANALYSIS; STEADY STATE; TREATMENT OUTCOME;

ADULT; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; MIGRAINE DISORDERS; PIPERIDINES; RECEPTORS, NEUROKININ-1; RECURRENCE; TREATMENT OUTCOME;

EID: 0034987623     PISSN: 03331024     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-2982.2001.00161.x     Document Type: Article

References (14)

1. Migraine: A vasomotor instability of the meningeal circulation
2. Neurotransmitters and the fifth cranial nerve: Is there a relation to the migraine headache phase of migraine?
3. Perivascular meningeal projections from cat trigeminal ganglia; possible pathway for vascular migraine headaches in man
4. Experimental studies on migraine headache: Pain-sensitive structures in the head and their significance in migraine headache
5. Neurogenically mediated leakage of plasma protein occurs from blood vessels in dura mater but not in brain
6. The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater
7. Ineffectiveness of neurokinin-1 antagonist in acute migraine: A crossover study
8. LY303870, a centrally active neurokinin-1 antagonist with a long duration of action
9. Classification and diagnosis criteria for migraine headache disorders, cranial neuralgias and facial pain
10. Study of the analgesic effect of lanepitant in patients with osteoarthritis pain
11. Pharmacological versus non-pharmacological prophylaxis of recurrent migraine headache: A meta-analytic review of clinical trials
12. In vitro and in vivo predictors of the antiemetic activity in tachykinin NK-1 receptor antagonists
13. Pharmacological blockade or genetic deletion of substance P (NK (1)) receptors attenuates neonatal vocalisation in guinea-pigs and mice
14. Substance P antagonist RPR 100893-201 is not effective in human migraine attacks